Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral nicorandil to reduce contrast-induced complications in cardiac catheterization
IRCT20210620051631N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of nicorandil in contrast-induced nephropathy (CIN) and coronary arteriosclerosis, sponsored by Mashhad University of Medical Sciences. Started Dec 2021; status: completed.
02
Drugs
nicorandil
03
Conditions
contrast-induced nephropathy (CIN)coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20210620051631N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210620051631N1.